Purple Biotech Ltd. (PPBT) experienced an increase of 5.34% in the premarket despite any official news. However, the last trading session closed at $2.62.
Appointment of Ori Hershkovitz – Latest News by PPBT
On 6th January 2022, PPBT announced that Ori Hershkovitz has been appointed a member of the Board of directors. Over the course of his career, Mr. Hershkovitz has worked in a variety of capacities in life sciences investment funds. Moreover, he currently serves on the boards of private and public biotechnology firms. He was the Managing Partner and Chief Investment Officer of Nexthera Fund. It is a New York-based healthcare hedge fund with over $400 million in assets under management, from 2015 to 2019. Lastly, he was the Founding Partner and Head of Research at Sphera Fund in Tel-Aviv from 2006 to 2014, where he oversaw the management of over $700 million in assets.
Now what?
The company welcomes Ori to the Purple Biotech Board of Directors very happily. In addition, the company has spent a significant amount of time investing in and coaching early-stage life sciences startups. As PPBT continues to execute on the corporate growth plans, the company looks forward to leveraging its industry and financial knowledge.
Appointment of Chief Business Officer by PPBT – What’s going on?
On 9th December 2021, PPBT announced the appointment of Fabien Sebille as Chief Business Officer. Fabien’s extensive scientific background and substantial business development expertise are best for the job of Chief Business Officer. Furthermore, the company is happy to have him join the team, and the company anticipates Fabien leading the business growth efforts. Fabien’s expertise will be essential to the company strategy and objectives as they continue to advance the promising oncology-focused pipeline, led by CM24 and NT219, and search for future growth possibilities.
Initiation of Part 2 of Phase 1/2 Clinical Trial – What’s new?
On 6th December 2021, PPBT reported that the ongoing phase of the clinical trial meant to evaluate NT219 has been initiated. The progression of the ongoing Phase 1/2 clinical trial to Part 2 is an important achievement. The early signs of efficacy, as well as safety patterns, seen in Part 1 of the research, have encouraged them. Lastly, in the first half of 2022, the company anticipates the release of more preliminary effectiveness data from Part 1 of the study.
